Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
About this item
Full title
Author / Creator
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Women with metastatic breast cancer that had progressed during treatment with trastuzumab plus a taxane were assigned to lapatinib plus capecitabine or to trastuzumab emtansine. The response rate and survival were significantly better with trastuzumab emtansine.
Amplification of human epidermal growth factor receptor 2 (HER2, also called ErbB2)...
Alternative Titles
Full title
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5125250
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5125250
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1209124
